Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890388 | 1.00 | KDM4E (0.42) | KDM4EGLAHPGDGAAMAPT | |
| SCHEMBL356359 | 1.00 | KDM4E (0.42) | KDM4EGLAHPGDGAAMAPT | |
| SCHEMBL12432342 | 0.95 | KMT2A (0.40) | KDM4EGLAHPGDGAAMAPT | |
| SCHEMBL29484192 | 0.95 | KMT2A (0.40) | KDM4EGLAHPGDGAAMAPT | |
| SCHEMBL18206532 | 0.91 | KDM4E (0.38) | KDM4EGLAHPGDGAAMAPT | |
| SCHEMBL18206533 | 0.91 | KDM4E (0.38) | KDM4EGLAHPGDGAAMAPT | |
| SCHEMBL18206529 | 0.91 | KDM4E (0.38) | KDM4EGLAHPGDGAAMAPT | |
| SCHEMBL31587441 | 0.88 | CTSK (0.45) | KDM4EHPGDCA2KMT2APREP | |
| SCHEMBL2580872 | 0.87 | PREP (0.39) | KDM4EHPGDCA1CA2CA7 | |
| SCHEMBL6159871 | 0.86 | PREP (0.44) | KDM4EHPGDCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112060793-B | Corrugated carton gradient color pattern flexible printing process | 安徽美盈森智谷科技有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-112060793-A | Corrugated carton gradient color pattern flexible printing process | 安徽美盈森智谷科技有限公司 | 2020-12-11 | — | — | CN | claimed |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| EP-4087583-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIBRANT HOLDINGS LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3897622-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12454771-B2 | Substrates, peptide arrays, and methods | VIBRANT HOLDINGS LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-10-16 | — | — | US | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-4711879-A | IMMUNO-MODULATING ACTIVITY | CIBA-GEIGY CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| EP-0214659-A2 | Peptide derivatives, process for the production thereof and pharmaceutical compositions containing same | GREEN CROSS CORPORATION (JP) | 1987-03-18 | — | — | EP | disclosed |
| US-4640911-A | IMMUNOSTIMULANTS, VIRICIDES SUCH AS HERPES SIMPLEX | CIBA-GEIGY CORPORATION (US) | 1987-02-03 | — | — | US | disclosed |
| EP-0193904-A2 | Amino acid derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
| EP-0192611-A2 | Acylated hexose derivatives and method for their preparation | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
| EP-0163286-A2 | Acylated sugars, method for their preparation and their use | CIBA-GEIGY AG (CH) | 1985-12-04 | — | — | EP | disclosed |
| US-4548923-A | IMMUNOSTIMULANTS, BACTERICIDES, VIRICIDES | CIBA GEIGY CORPORATION (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0099578-A1 | Muramyl peptides and method for their preparation | CIBA-GEIGY AG (CH) | 1984-02-01 | — | — | EP | disclosed |
| US-4299820-A | CARDIOVASCULAR DISORDERS | PFIZER INC. (US) | 1981-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIP, CALCB, SPPL2B | KDM4E 4396/4885GLA 4499/4885HPGD 4065/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | KDM4E 1344/4885GLA 2598/4885HPGD 4643/4885 |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ARG1, ARG2, PRMT1 | KDM4E 1438/4885GLA 2937/4885HPGD 459/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | KDM4E 406/4885GLA 1454/4885HPGD 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.